Theranexus Société Anonyme (ALTHX.PA)
EUR 0.64
(32.37%)
EUR 0.64
(32.37%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.44 Million EUR | -12.21% |
| 2022 | 2.78 Million EUR | 1544.41% |
| 2021 | -192.75 Thousand EUR | 93.59% |
| 2020 | -3 Million EUR | -363.88% |
| 2019 | -648.13 Thousand EUR | 82.43% |
| 2018 | -3.68 Million EUR | -33.81% |
| 2017 | -2.75 Million EUR | -556.6% |
| 2016 | 603.73 Thousand EUR | 36.84% |
| 2015 | 441.2 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 2.51 Million EUR | 0.0% |
| 2023 Q2 | -894.5 Thousand EUR | 0.0% |
| 2023 Q4 | 2.44 Million EUR | 0.0% |
| 2023 FY | 2.44 Million EUR | -12.21% |
| 2022 Q2 | 1.04 Million EUR | 0.0% |
| 2022 FY | 2.78 Million EUR | 1544.41% |
| 2022 Q4 | 2.78 Million EUR | 0.0% |
| 2021 Q2 | -878.06 Thousand EUR | 0.0% |
| 2021 FY | -192.75 Thousand EUR | 93.59% |
| 2021 Q4 | -192.75 Thousand EUR | 0.0% |
| 2020 Q2 | -7.07 Million EUR | 0.0% |
| 2020 Q4 | -3 Million EUR | 0.0% |
| 2020 FY | -3 Million EUR | -363.88% |
| 2019 FY | -648.13 Thousand EUR | 82.43% |
| 2019 Q4 | -648.13 Thousand EUR | 0.0% |
| 2019 Q2 | -57.83 Thousand EUR | 0.0% |
| 2018 Q2 | -6.58 Million EUR | 0.0% |
| 2018 Q4 | -3.68 Million EUR | 0.0% |
| 2018 FY | -3.68 Million EUR | -33.81% |
| 2017 Q2 | 1.13 Million EUR | 0.0% |
| 2017 FY | -2.75 Million EUR | -556.6% |
| 2017 Q4 | -2.75 Million EUR | 0.0% |
| 2016 Q4 | 603.73 Thousand EUR | 0.0% |
| 2016 FY | 603.73 Thousand EUR | 36.84% |
| 2015 FY | 441.2 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 442.319% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 101.244% |
| Adocia SA | 127 Thousand EUR | -1824.531% |
| Aelis Farma SA | -16.19 Million EUR | 115.095% |
| Biophytis S.A. | 2.7 Million EUR | 9.576% |
| Advicenne S.A. | 12.17 Million EUR | 79.925% |
| genOway Société anonyme | 2.97 Million EUR | 17.787% |
| IntegraGen SA | -709.74 Thousand EUR | 444.369% |
| Medesis Pharma S.A. | 1.15 Million EUR | -111.029% |
| Neovacs S.A. | -237.08 Thousand EUR | 1130.911% |
| NFL Biosciences SA | -2.27 Million EUR | 207.394% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 43.896% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 394.282% |
| Sensorion SA | 1.37 Million EUR | -77.341% |
| TME Pharma N.V. | -1.07 Million EUR | 326.52% |
| Valbiotis SA | -18.13 Million EUR | 113.475% |
| TheraVet SA | 12.78 Thousand EUR | -19017.364% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | -12.117% |
| argenx SE | -1.83 Billion EUR | 100.133% |
| BioSenic S.A. | 28.04 Million EUR | 91.285% |
| Celyad Oncology SA | -6.1 Million EUR | 140.055% |
| DBV Technologies S.A. | -114.95 Million USD | 102.126% |
| Galapagos NV | -157.2 Million EUR | 101.555% |
| Genfit S.A. | -7.61 Million EUR | 132.113% |
| GeNeuro SA | 5.91 Million EUR | 58.647% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 109.733% |
| Innate Pharma S.A. | -30.71 Million EUR | 107.958% |
| Inventiva S.A. | 10.48 Million EUR | 76.698% |
| MaaT Pharma SA | -10.2 Million EUR | 123.951% |
| MedinCell S.A. | 39.5 Million EUR | 93.812% |
| Nanobiotix S.A. | -24.71 Million EUR | 109.888% |
| Onward Medical N.V. | -12.89 Million EUR | 118.956% |
| Oryzon Genomics S.A. | 1.43 Million EUR | -70.88% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 90.991% |
| Oxurion NV | 10.71 Million EUR | 77.179% |
| Pharming Group N.V. | 99.4 Million EUR | 97.541% |
| Poxel S.A. | 44.55 Million EUR | 94.515% |
| GenSight Biologics S.A. | 16.29 Million EUR | 85.0% |
| Transgene SA | -14.4 Million EUR | 116.963% |
| Financière de Tubize SA | 78.62 Million EUR | 96.891% |
| UCB SA | 2.17 Billion EUR | 99.888% |
| Valneva SE | 82.73 Million EUR | 97.046% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 113.195% |